Get startedLog in
    Picture of Emcure Pharmaceuticals logo

    EMCURE — Emcure Pharmaceuticals Cashflow Statement

    0.000.00%
    in flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Emcure Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

    2021
    March 31st
    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:PROSPECTUSPROSPECTUSPROSPECTUSPROSPECTUSARS
    Standards:
    IAS
    IAS
    IAS
    IAS
    IAS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line6,5739,7257,4727,2729,713
    Depreciation
    Non-Cash Items2,5881,5392,3222,3071,674
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-5,350-3,890-4,927-1,731-6,712
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities7,0449,8237,46910,9728,517
    Capital Expenditures-1,457-3,970-4,034-3,071-4,069
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-1,062-3,918-643-4,0543,129
    Acquisition of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-2,518-7,888-4,677-7,125-940
    Financing Cash Flow Items-1,953-2,178-2,229-2,706-1,287
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-1,889-1,519-1,454-1,642-8,140
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash2,5914191,3362,185-583